Compare Aterian Inc (ATER) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aterian Inc vs Davita Inc — how do they compare? Aterian Inc trades at $0.48 (market cap $5.22M), while Davita Inc trades at $178.34 (market cap $11.72B). The key difference: Davita Inc is far larger — about 2245.2× Aterian Inc's market cap, and Davita Inc is trading nearer its 52-week high, Aterian Inc nearer its low. Which is the better fit depends on your goals.
| ATER | DVA | |
|---|---|---|
Market Cap | $5.22M | $11.72B |
Sector | Consumer Cyclical | Health |
52-Week High | $1.39 | $240.96 |
52-Week Low | $0.36 | $103.87 |
Enterprise Value | $5.80M | $24.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aterian (ATER) trades at $0.4934, up 7.03% in the last 24 hours, with a bearish technical signal overall. The company reported revenue of $68.98 million in 2025 but a net loss of $18.98 million, showing negative margins despite recent earnings beats. Recent news highlights a pending asset sale vote that could return $0.85–$1.14 per share to stockholders, creating near-term event-driven volatility.
The outlook hinges on the asset sale outcome, offering potential shareholder returns but also signaling business contraction. Risks include persistent cash burn, declining revenue, and high negative equity. Analysts are split 50/50 buy/hold, reflecting uncertainty amid restructuring efforts.
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aterian Inc
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products, and consumer electronics. It has various owned and operated brands include Vremi, Healing Solutions, Xtava, TRUWEO, Spiralize, Pohl+Schmitt, and RIF6. The company generates revenue through the online sales of various consumer products that are sold online.
Read more on ATER →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
